Gt Biopharma Stock Price on February 18, 2021
| GTBP Stock | USD 3.23 0.01 0.31% |
Below is the normalized historical share price chart for GT Biopharma extending back to November 05, 1984. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of GT Biopharma stands at 3.23, as last reported on the 8th of May, with the highest price reaching 3.29 and the lowest price hitting 3.17 during the day.
If you're considering investing in GTBP Stock, it is important to understand the factors that can impact its price. GT Biopharma retains Efficiency (Sharpe Ratio) of -0.0823, which attests that the entity had a -0.0823% return per unit of price deviation over the last 3 months. GT Biopharma exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out GT Biopharma's Market Risk Adjusted Performance of 1.81, information ratio of (0.13), and Coefficient Of Variation of (860.25) to validate the risk estimate we provide.
At this time, GT Biopharma's Other Stockholder Equity is relatively stable compared to the past year. As of 05/08/2024, Issuance Of Capital Stock is likely to grow to about 10.2 M, while Common Stock Shares Outstanding is likely to drop slightly above 1.3 M. . As of 05/08/2024, Price To Sales Ratio is likely to drop to 2,293. In addition to that, Price Earnings Ratio is likely to grow to -1.29. GTBP Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 22nd of September 2017 | 200 Day MA 6.4113 | 50 Day MA 4.0739 | Beta 0.571 |
GTBP |
Sharpe Ratio = -0.0823
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GTBP |
Estimated Market Risk
| 5.82 actual daily | 51 51% of assets are less volatile |
Expected Return
| -0.48 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average GT Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GT Biopharma by adding GT Biopharma to a well-diversified portfolio.
Price Book 0.6178 | Book Value 5.414 | Enterprise Value -9.5 M | Enterprise Value Ebitda 1.2588 | Shares Float 1.2 M |
GT Biopharma Valuation on February 18, 2021
It is possible to determine the worth of GT Biopharma on a given historical date. On February 18, 2021 GTBP was worth 2.29 at the beginning of the trading date compared to the closed value of 63.9. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of GT Biopharma stock. Still, in general, we apply an absolute valuation method to find GT Biopharma's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of GT Biopharma where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against GT Biopharma's related companies.
| Open | High | Low | Close | Volume | |
04/25/2022 | 2.29 | 63.90 | 63.90 | 63.90 | 5,265 |
| 2.10 | 60.30 | 60.30 | 60.30 | 5,900 |
| Backtest GT Biopharma | | | GT Biopharma History | | | GT Biopharma Valuation | Next |
GT Biopharma Trading Date Momentum on February 18, 2021
The event impact on price volatility cannot be determined at this time. Please check this event after some time to allow current data to be analyzed.GT Biopharma Fundamentals Correlations and Trends
By evaluating GT Biopharma's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among GT Biopharma's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. GTBP financial account trend analysis is a perfect complement when working with valuation or volatility modules.About GT Biopharma Stock history
GT Biopharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for GTBP is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in GT Biopharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing GT Biopharma stock prices may prove useful in developing a viable investing in GT Biopharma
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 1.3 M | 1.3 M | |
| Net Loss | -52.2 M | -54.8 M |
GT Biopharma Stock Technical Analysis
GT Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
GT Biopharma Period Price Range
Low | April 25, 2022
| High |
2.29 | 63.90 |
GT Biopharma May 8, 2024 Market Strength
Market strength indicators help investors to evaluate how GT Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading GT Biopharma shares will generate the highest return on investment. By undertsting and applying GT Biopharma stock market strength indicators, traders can identify GT Biopharma entry and exit signals to maximize returns
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 27.9 | |||
| Day Median Price | 63.9 | |||
| Day Typical Price | 63.9 | |||
| Price Action Indicator | 30.81 | |||
| Period Momentum Indicator | (60.67) | |||
| Relative Strength Index | 44.55 |
GT Biopharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for GT Biopharma's price direction in advance. Along with the technical and fundamental analysis of GTBP Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of GTBP to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.69) | |||
| Total Risk Alpha | (1.35) | |||
| Treynor Ratio | 1.8 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.Note that the GT Biopharma information on this page should be used as a complementary analysis to other GT Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for GTBP Stock analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is GT Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.58) | Return On Assets (0.55) | Return On Equity (0.79) |
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.